Medexus Pharmaceuticals Inc. (TSE:MDP) Receives Consensus Rating of “Buy” from Analysts

Medexus Pharmaceuticals Inc. (TSE:MDP) has been given an average recommendation of “Buy” by the seven analysts that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and four have given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is C$5.49.

MDP has been the subject of several analyst reports. Leede Financial raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, January 22nd. Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Ventum Financial upped their target price on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a “buy” rating in a research note on Thursday, January 30th. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Finally, Stifel Nicolaus cut shares of Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price target for the stock from C$6.00 to C$3.45 in a report on Friday, February 7th.

Medexus Pharmaceuticals Stock Down 6.5 %

Shares of MDP opened at C$2.15 on Friday. The company has a market cap of C$48.13 million, a P/E ratio of 10.28 and a beta of 1.96. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$5.56. The firm’s 50 day moving average price is C$2.93 and its 200 day moving average price is C$2.91.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.